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Abstract: Neurotrophic keratitis (NK) is a degenerative corneal disease caused by damage of 
trigeminal corneal innervation, which leads to spontaneous epithelial breakdown and corneal 
ulceration. The impairment of corneal sensory innervation causes the reduction of both protective 
reflexes and trophic neuromodulators that are essential for the vitality, metabolism, and wound 
healing of ocular surface tissues. A wide range of ocular and systemic conditions, including 
herpetic keratitis, ocular chemical burns, corneal surgery, diabetes, multiple sclerosis, and 
neurosurgical procedures, can cause NK by damaging trigeminal innervation. Diagnosis of NK 
requires careful investigation of any ocular and systemic condition associated with the disease, 
complete ocular surface examination, and quantitative measurement of corneal sensitivity. The 
clinical stages of NK range from corneal epithelial alterations (stage 1) to persistent epithelial 
defect (stage 2) and ulcer (stage 3), which may progress to corneal perforation. Management of 
NK is based on clinical severity, and the aim of the therapy is to halt the progression of corneal 
damage and promote epithelial healing. Although several medical and surgical treatments have 
been proposed, no therapies are currently available to restore corneal sensitivity, and thus, NK 
remains difficult and challenging to treat. The purpose of this review is to summarize available 
evidence on the pathogenesis, diagnosis, and treatment of NK. Novel medical and surgical 
therapies including the topical administration of nerve growth factor and corneal neurotization 
are also described.
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Introduction
Neurotrophic keratitis (NK) is a rare degenerative corneal disease caused by damage 
of trigeminal innervation. Corneal nerves play an essential role in tear production 
and preservation of the normal metabolism and function of the ocular surface. Loss 
of sensitivity impairs corneal wound healing, leading to epithelial changes including 
punctate epithelial keratopathy, persistent epithelial defects, and corneal ulcer.1
Various ocular and systemic diseases can cause damage to the fifth cranial nerve 
at different levels, from the trigeminal nucleus to the corneal nerve endings. Common 
causes are herpetic keratitis, diabetes, chemical or surgical damage, and neurosurgi-
cal procedures.2,3 Medical treatment consists mainly of supportive measures that do 
not address the underlying cause of the disease. Recently, novel promising treatments 
have been proposed and are currently under evaluation. These include mainly topical 
treatment with nerve growth factor (NGF) and surgical corneal neurotization. Such 
approaches target the pathogenic elements of NK, carrying the potential of restoring 
normal corneal innervation and sensitivity.
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The cornea is innervated by the ophthalmic branch of the 
trigeminal nerve as well as by autonomic nerves. Nerve 
bundles enter the cornea at the limbus, move toward the center 
below the anterior third of the stroma, penetrate Bowman’s 
layer, and create a dense network of nerve fibers between 
Bowman’s layer and basal epithelial cells (i.e., sub-basal 
nerve plexus).4 The great number of sensory nerve endings 
makes the cornea the most densely innervated tissue in the 
human body.5 Nerves have a key role in maintaining a healthy 
ocular surface, both by triggering protective reflexes after 
injury, and by providing trophic factors to the corneal cells. 
Corneal denervation causes decreased vitality, metabolism, 
and mitosis of epithelial cells, with subsequent epithelial 
changes including intracellular edema, loss of microvilli, and 
abnormal development of the basal lamina.6,7
Corneal sensory innervation reacts to mechanical, 
chemical, and thermal stimuli with two reflex arcs: a motor 
arc eliciting blinking, and an autonomous arc stimulating 
tear secretion. Therefore, the reduction of corneal sensation 
impairs these two reflexes with an alteration of production 
and stability of the tear film.8
Corneal nerves and epithelial cells support each other 
mutually through the release of trophic factors promoting 
epithelial cell proliferation, migration, and differentiation 
as well as nerve development and survival. Corneal nerves 
express many epitheliotrophic neuromediators, such as 
substance P, calcitonin gene-related peptide, acetylcholine, 
noradrenaline, serotonin, neuropeptide Y, and vasointestinal 
peptide. On the other side, corneal epithelial cells release 
various neurotrophic growth factors, including NGF, ciliary 
neurotrophic factor, and glial-cell-derived neurotrophic fac-
tor. These factors are fundamental in ocular surface homeo-
stasis and wound healing.4
In particular, NGF is a neurotrophin discovered in the 
early 1950s by R. Levi-Montalcini that promotes neuronal 
sprouting by intact and injured neurons. It provides trophic 
support to neurons after injury and reverses pathologic 
changes induced by peripheral nerve damage.9 NGF exerts 
its biologic functions by binding to low-affinity p75NTR 
(neurotrophin receptor, a member of the tumor necrosis fac-
tor receptor superfamily) and high-affinity TrkA receptor (a 
tyrosine kinase receptor family). The human cornea produces 
NGF and expresses high-affinity NGF receptors.10 NGF dem-
onstrated an important role in the integrity and function of 
the ocular surface, stimulating both epithelial and nerve fiber 
proliferation and survival.11 In vivo studies proved that NGF 
concentration increases after injury, and that administration 
of NGF accelerates corneal healing.10
These complex reciprocal relations between epithelial 
cells and nerves are crucial for the corneal physiologic 
renewal and wound healing. An impairment of corneal sen-
sitivity interrupts these trophic relations and may produce 
the pathologic changes typical of NK.
Causes
All conditions that impair trigeminal innervation at any 
level can cause NK, such as ocular surface diseases, sys-
temic diseases, and central or peripheral nervous damages 
(Figure 1).12,13
Herpes simplex and herpes zoster eye infections are 
among the most common conditions leading to corneal 
anesthesia. In a large case series from Bonini et al, herpetic 
keratitis was the most common cause of NK (27% of the 
patients).2 A severe reduction of sub-basal nerve plexus 
density was demonstrated in herpetic keratitis.14
Corneal surgeries like laser-assisted in situ keratomi-
leusis, keratoplasty, and corneal incisions for cataract may 
disrupt corneal innervation and cause NK.15,16 After nerve 
transection at the peripheral cornea, the distal nerves undergo 
Wallerian degeneration with immediate loss of sensation to 
the corresponding region. Nerve regeneration occurs gradu-
ally over months with variable return of corneal sensitivity.15 
Other ocular surface conditions associated with NK are 
corneal chemical and traumatic injuries, corneal dystrophies, 
contact lens wearing, and chronic use of topical medications 
(such as anesthetics, beta-blockers, antivirals, glaucoma 
medications, antibiotics, and nonsteroidal anti-inflammatory 
drugs).12,13
Surgical procedures for the treatment of trigeminal 
neuralgia may induce permanent damage to the trigeminal 
nerve with subsequent corneal anesthesia. The main surgi-
cal options include microvascular decompression, balloon 
compression, radiofrequency thermocoagulation, and gamma 
knife radiosurgery. The intraoperative damage occurs at 
the preganglionic or ganglionic region of the nerve and is 
not associated with a reduction of sub-basal nerve plexus 
density.17 Other less common causes of trigeminal palsy are 
intracranial and orbital tumors, facial trauma, aneurysm, 
and stroke.1,12
Systemic conditions like diabetes, multiple sclerosis, and 
leprosy may impair corneal sensitivity and cause NK. In par-
ticular, neuropathy is one of the most common complications 
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Neurotrophic keratitis: challenges and prospects
of myelinated nerve fibers. The extent of nerve damage has 
been demonstrated to be associated with the duration of 
hyperglycemia.18 Corneal nerve evaluation in patients with 
diabetes has shown that the decreased corneal sensitivity 
was related to a reduction of sub-basal nerve density, with 
abnormally tortuous nerve fiber bundles. Additionally, a cor-
relation between the decrease of corneal sensitivity and the 
degree of somatic polyneuropathy was found.18 Recent stud-
ies using in vivo confocal microscopy (IVCM) have reported 
an association between levels of glycated hemoglobin and 
the density of corneal innervation.19
Long-term systemic therapy with antipsychotics and 
antihistamines may also cause NK. Very rare congenital 
causes of NK include Riley–Day syndrome, Moebius syn-
drome, Goldenhar–Gorlin syndrome, and congenital corneal 
anesthesia.12
Clinical presentation
The clinical presentation of NK is characterized by well-
defined and progressive ocular surface changes, which 
are caused by the loss of sensitivity, regardless the cause 
of trigeminal damage. A three-stage classification of NK 
based on severity of corneal damage was introduced by 
Mackie.1
Stage 1 is characterized by corneal abnormalities such 
as punctate keratopathy, corneal edema, corneal epithelial 
hyperplasia, and irregularity (Figure 2A). Rose Bengal 
 staining of the conjunctiva, increased tear viscosity, and 
decreased breakup time are often associated. In long-standing 
cases, stromal scarring and superficial corneal neovascular-
ization may develop.
Stage 2 is characterized by a recurrent or persistent epi-
thelial defect, commonly located paracentrally in the superior 
half of the cornea. The epithelial defect is often delimited by 
smooth, rolled, and loose edges of an opaque and edematous 
epithelium (Figure 2B). Stromal edema with Descemet’s 
membrane folds may be observed and sometimes anterior 
chamber inflammation is associated.
Stage 3 is characterized by corneal ulcer (Figure 2C). 
The stromal melting may progress to corneal thinning and 
eventually perforation. This may occur without significant 
ocular symptoms because of impaired corneal sensitivity; 
however, patients may complain of blurred vision in case of 
corneal ulcer, edema, or scarring.1,12
Diagnosis
Patient’s clinical history should be accurately collected and 
reviewed to identify any ocular or systemic disease potentially 
Figure 1 Common causes of neurotrophic keratitis.





Chemical and thermal injuries
Surgery (LASIK, keratoplasty, cataract)
Contact lens wear






































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





associated with the disorder, such as ocular surface conditions 
(e.g., previous herpetic infection, ocular surgery, chemical 
burns, topical drug use, contact lens wearing), systemic 
diseases (e.g., diabetes, multiple sclerosis), and neurologic 
conditions (e.g., brain tumors, neurosurgery, stroke, trauma).
A careful ocular surface examination should be per-
formed. In particular, eyelids should be examined to rule 
out the presence of lagophthalmos or blepharitis. Slit-lamp 
examination is fundamental to detect sings of NK and to clas-
sify NK severity, ranging from punctate corneal keratopathy 
to stromal melting and corneal perforation. Corneal anesthe-
sia causes lack of ocular discomfort symptoms; thus, NK 
should be always suspected in case of significant discrepancy 
between ocular signs and symptoms. Ocular examination 
helps to identify also possible causes of decreased corneal 
sensitivity: corneal scarring may indicate previous injuries 
or infections; patchy iris atrophy may be a sign of previous 
herpetic infection. Fundus examination may show signs of 
diabetic retinopathy or optic nerve abnormalities due to 
intracranial pathology.12,13
Vital staining with fluorescein or lissamine green is useful 
to assess corneal and conjunctival epithelial integrity. Tear 
film production and stability should be evaluated with lac-
rimal function tests. It is known that neurotropic keratitis is 
associated with an increase of tear osmolarity and a decrease 
of both Schirmer test and tear breakup time values.8,20
The decrease or absence of corneal sensitivity is the 
diagnostic hallmark of NK. Corneal sensitivity can be quan-
titatively measured by Cochet–Bonnet esthesiometer, which 
employs a nylon monofilament of adjustable length touch-
ing the cornea and recording the patient’s response. Each 
quadrant of the cornea may be tested. As the length of the 
filament is decreased, the pressure transmitted is increased.21 
The noncontact Belmonte esthesiometer is another device 
allowing to investigate also chemical and thermal corneal 
sensitivity.22 However, it is typically reserved for research 
purposes, and not routinely used in clinical practice to date.
IVCM is a noninvasive imaging technique that allows the 
in vivo study of the different layers of the ocular surface at a 
cellular level. IVCM has been used to evaluate corneal nerve 
morphology in healthy and diseased corneas. A significant 
reduction of corneal nerve density strongly correlated with 
the decrease of corneal sensation was shown in patients with 
NK.14–18 In addition, IVCM showed also a higher number 
of hyper-reflective keratocytes and a lower epithelial and 
endothelial cell density in patients with NK.16 These findings 
suggest that corneal sensory nerves play a role also in the 
function and survival of the corneal endothelium.
Treatment
Treatment approach of NK should be prompt and based on 
the stage and severity of the disease. Despite various medical 
and surgical therapies having been proposed, NK remains 
yet difficult and challenging to treat, and the lack of posi-
tive response is commonly observed in the clinical practice.
In stage 1, the therapy aims at preventing an epithelial 
breakdown and improving epithelial quality. All topical and 
systemic medications associated with ocular surface toxicity 
should be discontinued. Preservative-free tear substitutes 
and lubricant ointments are useful to improve lubrication 
and ocular surface health. Other associated ocular surface 
diseases, such as dry eye, exposure keratitis, and limbal stem 
cell deficiency, should be properly treated.12
In stage 2, therapy is addressed to promote healing of the 
epithelial defect, and to prevent the progression to corneal 
ulcer. Patient should be monitored frequently, because the 
Figure 2 Three-stage classification of neurotrophic keratitis.
Note: Stage 1: cloudy and irregular corneal epithelium (A); stage 2: large epithelial 
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Neurotrophic keratitis: challenges and prospects
progression to stromal melting and perforation may occur 
without any symptom. Topical antibiotics are recommended 
in this stage to prevent infections. On the contrary, topical 
steroids should be used with caution, because they may inhibit 
the healing process and increase the risk of corneal melting. 
Therapeutic contact lenses are useful to promote corneal 
healing, maintaining a fluid layer in stable contact with the 
cornea, and protecting it from the rubbing of the eyelids. 
However, attention should be paid because of the increased 
risk of infections.23
Autologous serum eye drops have become increasingly 
popular for treating ocular surface disorders, including NK.24 
Autologous serum contains several natural components of 
the normal tears, such as growths factors, neuromediators, 
cytokines, and vitamins.25 These substances are known to 
promote proliferation, migration, and differentiation of 
the ocular surface epithelium, and are essential in corneal 
homeostasis and wound healing.26 Matsumoto et al reported 
the complete healing of all the 14 eyes with NK treated with 
autologous serum drops and an increase in corneal sensitivity 
in 64.2% of cases.26 The study demonstrated that serum har-
bors neurotrophins and growth factors to the ocular surface. 
Other more recent studies confirmed that autologous serum 
eye drops allowed high rates of corneal healing, and also the 
improvement of corneal nerve morphology with increased 
number, length, width, and density detected by IVCM.27–29
The use of autologous serum may be inconvenient or con-
traindicated in patients with coexisting general conditions, 
such as anemia and blood discrasia. Therefore, the use of allo-
geneic sera obtained from healthy donors has been proposed 
as a viable alternative. Among these, umbilical cord blood 
serum is rich of epitheliotrophic growth factors, with higher 
levels of epidermal growth factor, insulin-like growth factor, 
transforming growth factor-beta, and vascular endothelial 
growth factors compared to peripheral blood serum.30,31 It 
has been shown that umbilical cord blood serum eye drops 
is effective in treating NK, achieving a complete corneal 
healing in all the patients under study.32 A recent IVCM 
study showed an improvement in corneal nerve morphology 
in patients treated with umbilical cord serum eye drops, with 
an increase of total nerve number and a decrease of nerve 
tortuosity.33 Two randomized clinical trials are currently ongo-
ing to evaluate safety and efficacy of topical umbilical cord 
blood serum and plasma rich in growth factors in patients 
with NK (NCT02707120, NCT03084861).
Surgical treatment is usually limited to corneal ulcers 
(stage 3) not responding to medical treatment, and/or to 
the related complications. Several approaches are available, 
including tarsorraphy, conjunctival flap, and amniotic mem-
brane transplantation. Tarsorraphy is the most commonly 
used procedure to promote corneal healing in NK. It reduces 
the width of the palpebral fissure, protecting the cornea 
from the traumatic rubbing of eyelids and decreasing tear 
evaporation rate.34 However, the poor cosmetic outcome is 
often a major concern for patients. The injection of Botulin A 
toxin into the superior elevator palpebrae superioris muscle 
is an effective alternative, allowing also an easier and better 
examination of the ocular surface compared to tarsorraphy.35
The use of conjunctival flaps was first proposed by 
Gundersen in 1958 and became a standard surgical procedure 
to treat corneal ulcers with or without perforation.36 After a 
360° peritomy, a pedunculated conjunctival flap is mobilized 
from the upper bulbar conjunctiva and sutured to the con-
junctiva in the lower limbus to cover the affected cornea. The 
conjunctival flap provides metabolic and mechanical support 
for corneal healing, thanks to the conjunctival blood vessels, 
which transport nutrients and growth factors to the corneal 
surface.37 The procedure restores the anatomical integrity of 
the ocular surface but sacrifices visual function.
Amniotic membrane transplantation has been success-
fully used to treat corneal ulcers and persistent epithelial 
defects from different causes, including NK.38,39 The amniotic 
membrane provides mechanical protection, releases growth 
factors, and supports epithelial cell adhesion and prolifera-
tion.38 Evidence from a randomized controlled trial showed 
that both amniotic membrane transplantation and conven-
tional management (tarsorraphy or therapeutic contact lenses) 
are effective in treating refractive NK.40
Small perforations can be effectively treated with cyano-
acrylate gluing followed by application of a bandage contact 
lens, whereas lamellar or penetrating keratoplasty is required 
for larger defects.41 However, persistent anesthesia causes 
impaired wound healing and a high risk of recurrence of 
corneal ulceration in the graft. This explains the low success 
rate of corneal transplantation in patients with NK.
Three cases from our cohort patients, which may be 
representative of different history and course of the disease, 
are shown in Figure 3. Explanation of each case is given in 
the legend.
Future prospects
NK was traditionally considered an orphan disease with no 
effective treatment. In recent years, novel promising medical 
and surgical treatments have been developed and are cur-
rently under investigation. Recent articles of novel medical 
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Figure 3 Slit-lamp pictures of a case of severe post-herpetic neurotrophic keratitis (case #1, A and B).
Notes: A: Paracentral corneal neurotrophic ulcer with neovessels at the time of presentation. Preserved antibiotic and antiviral topical therapies were discontinued, while 
topical unpreserved tear substitutes and nocturnal ointments were started, in combination with oral antiviral therapy. B: After 8 months, the clinical picture worsened with 
impending central corneal perforation. Slit-lamp pictures of a case of neurotrophic keratitis secondary to trigeminal nerve damage from intracranial mass (case #2, C and 
D). C: Small neurotrophic corneal ulcer in the inferior region of the cornea. Topical treatment with preservative-free tear substitutes and nocturnal ointments was started. 
D: After 6 months, the epithelial defect did not completely heal. Slit-lamp pictures of a corneal neurotrophic ulcer in a diabetic patient (case #3, E and F). E: Large corneal 
neurotrophic ulcer in the inferotemporal region of the cornea. The patient was treated with topical preservative-free tear substitutes and nocturnal ointments. F: Three 




Table 1 Novel medical treatments for neurotrophic keratitis






Aifa et al42 11 RGTA 1x/on alternate days >15 72.7% 60.9
Arvola et al43 6 RGTA 1x/on alternate days 45 33% 56
Dunn et al46 9 Thymosin beta-4 4x/day >42 67% 45
Nishida et al49 9 SP and IGF1 4x/day 141 89% 13.3
Yamada et al50 26 SP and IGF1 4x/day 96 73% 10.5
Lambiase et al51 14 NGF Every 2 h for 2 days, then 6x/day 45 100% 21
Bonini et al2 45 NGF Every 2 h for 2 days, then 6x/day 38 100% 22.8/26.6a
Lee et al54 27 Nicergoline (oral) 10 mg 2x/day >60 85% 15.6
Note: aRange (minimum/maximum).
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Neurotrophic keratitis: challenges and prospects
Regenerating agent (RGTA, Cacicol20®; OTR3, Paris, 
France) is a new matrix agent containing large polymers mim-
icking heparan sulfates. RGTA creates a microenvironment 
that induces cell migration and adhesion and promotes epi-
thelial healing. A Phase III clinical trial is currently ongoing 
(NCT01794312). In a recent study, topical drops containing 
RGTA achieved complete healing of corneal ulcer in 73% of 
11 patients with NK.42 Another work showed less favorable 
results, with a failure of corneal healing in 67% of treated 
patients.43 The combined therapy of RGTA and umbilical cord 
blood serum eye drops has been recently proposed, thanks 
to their synergistic effect.44 RGTA could replace destroyed 
heparan sulfates, protecting the bioavailability of growth 
factors and providing a matrix in which cells can migrate 
and multiply.45
Thymosin beta-4 is an intracellular protein with various 
functions in different cellular processes, including wound 
healing, suppression of inflammation and apoptosis, synap-
togenesis, and axon growth.46 The efficacy of topical treat-
ment with thymosin beta-4 in nine patients with NK was 
described in an open study that reported a complete corneal 
healing in six patients with corneal ulcers, while the remain-
ing three patients with punctuate epithelial defects did not 
show significant clinical changes.46 A randomized-controlled 
trial is currently ongoing to evaluate safety and efficacy of 
topical treatment with thymosin beta-4 in patients with NK 
(NCT02600429).
Topical substance P (SP) and insulin-like growth factor 1 
(IGF-1) stimulate synergistically the proliferation and migra-
tion of corneal epithelial cells both in vitro and in vivo.47,48 In 
two recent studies, patients with epithelial defects associated 
to NK were treated with eye drops containing a combination 
of an SP-derived peptide and IGF-1-derived peptide.49,50 The 
treatment induced the healing of the epithelial defects in 
89%49 and 73% of cases50 without any adverse side effect.
Topical treatment with NGF represents one of the most 
promising therapies for NK. NGF is a neurotrophin that 
promotes growth and survival of sensory and sympathetic 
neurons and can restore the function of injured neurons.9 
NGF demonstrated a key role in the immune modulation, 
trophism, and healing of the ocular surface.11 Two open-label 
studies tested murine-derived NGF in patients with moderate 
(stage 2) and severe (stage 3) NK. The treatment induced 
rapid corneal healing in all the patients, with improved cor-
neal sensitivity, tear production, and visual acuity without 
any adverse event.2,51 A recombinant human NGF eye drop 
formulation has been subsequently developed, and Phase 
I studies showed a good safety profile.52 Phase II trials are 
currently ongoing to evaluate the efficacy of two different 
formulations of this treatment in patients with NK stage 2 
and 3 (NCT02227147, NCT01756456).
Nicergoline is an ergoline derivative used to treat degen-
erative and vascular dementia. In animal rat models, it was 
shown to promote corneal healing and to increase NGF levels 
in the cornea.53 A recent study evaluated treatment with oral 
nicergoline in patients with NK, demonstrating a healing of 
the epithelial defect in 23 out of 27 eyes, with an improve-
ment of NGF levels and corneal sensitivity.54
Corneal neurotization is a novel and promising surgi-
cal procedure for NK, which can be performed through 
two different techniques, based on the transposition of the 
supraorbital and/or supratrochlear nerves (direct neurotiza-
tion),55,56 or on the sural nerve graft (indirect neurotization).57 
In the first technique, contralateral healthy supraorbital and 
supratrochlear nerves are harvested through a large coronal 
incision, tunneled across the bridge of the nose and inserted 
around the limbus of the anesthetic eye. Six patients with NK 
were treated with this technique, and all the patients showed 
the improvement of corneal health and sensitivity.55 Allevi 
et al performed corneal neurotization according to the same 
technique, combined with upper eyelid neurotized platysma 
graft, and followed by penetrating keratoplasty in a patient 
with associated seventh and fifth cranial nerve palsy. The 
overall procedure was successful allowing patient to regain 
corneal sensitivity, eyelid movement, and visual acuity.56 As 
the ipsilateral frontal nerve is still intact in case of isolated 
corneal anesthesia from local damage to the long ciliary 
nerves, ipsilateral supraorbital nerve can be used to directly 
neurotize the cornea, allowing the decrease of the size of 
the scalp incision and the extent of the dissection needed.58
In the indirect technique, corneal neurotization was 
performed using a sural nerve autograft anastomosed to the 
supratrochlear nerve and tunneled through the upper eyelid 
incision. Unlike the direct technique, this approach enables 
the management of bilateral NK and avoids the large bicoro-
nal incision. Four eyes with NK were included in the study: 
three of them had noticeably improved corneal sensitivity 
6 months after surgery.57 A recent cadaver feasibility study 
described a new minimally invasive technique for corneal 
neurotization using an endoscopic approach for direct nerve 
supraorbital nerve transfer.59 The potential advantages of the 
endoscopic corneal neurotization include smaller incisions, 
decreased operative and healing time, decreased forehead 
edema, less risk for facial nerve injury, and minimal blood 
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The patients gave their consent for the photographs to be 
used in medical publication.
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